Esperion Therapeutics, Inc.
Символ: ESPR
NASDAQ
2.05
USDПазарна цена днес
-1.0113
Съотношение P/E
0.1183
Коефициент PEG
349.36M
MRK Cap
- 0.00%
Доходност на DIV
Esperion Therapeutics, Inc. (ESPR) финансови отчети
Баланс
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2002 | 2001 | 2000 | 1999 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 497.89 | 82.2 | 124.8 | 208.9 | |||||||||||||||||
balance-sheet.row.short-term-investments | 17.43 | 0 | 42.1 | 50.4 | |||||||||||||||||
balance-sheet.row.net-receivables | 168.33 | 48.5 | 33.7 | 22.9 | |||||||||||||||||
balance-sheet.row.inventory | 202.09 | 65.6 | 35.2 | 34.4 | |||||||||||||||||
balance-sheet.row.other-current-assets | 20.89 | 4.7 | 9.9 | 62.8 | |||||||||||||||||
balance-sheet.row.total-current-assets | 902.02 | 201.1 | 246.7 | 329 | |||||||||||||||||
balance-sheet.row.property-plant-equipment-net | 11.3 | 4.7 | 1.2 | 2.6 | |||||||||||||||||
balance-sheet.row.goodwill | 0 | 0 | 0 | 0 | |||||||||||||||||
balance-sheet.row.intangible-assets | 0.22 | 0.1 | 0.1 | 0.1 | |||||||||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 0.22 | 0.1 | 0.1 | 0.1 | |||||||||||||||||
balance-sheet.row.long-term-investments | 0 | 0 | 42.1 | 50.4 | |||||||||||||||||
balance-sheet.row.tax-assets | 0 | 0 | 0 | -50.4 | |||||||||||||||||
balance-sheet.row.other-non-current-assets | -3.72 | 0 | -42.1 | 50 | |||||||||||||||||
balance-sheet.row.total-non-current-assets | 11.52 | 4.7 | 1.3 | 52.6 | |||||||||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | |||||||||||||||||
balance-sheet.row.total-assets | 913.55 | 205.8 | 247.9 | 381.6 | |||||||||||||||||
balance-sheet.row.account-payables | 99.56 | 31.7 | 23 | 17.6 | |||||||||||||||||
balance-sheet.row.short-term-debt | 38.29 | 36.4 | 0.4 | 1.4 | |||||||||||||||||
balance-sheet.row.tax-payables | 0 | 0 | 0 | 0 | |||||||||||||||||
balance-sheet.row.long-term-debt-total | 1288.3 | 501.5 | 260.6 | 258.8 | |||||||||||||||||
Deferred Revenue Non Current | 0 | 0 | 0 | 0.6 | |||||||||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 0 | - | - | - | |||||||||||||||||
balance-sheet.row.other-current-liab | 285.83 | 62.7 | 65.4 | 48.7 | |||||||||||||||||
balance-sheet.row.total-non-current-liabilities | 1983.59 | 504.6 | 479.4 | 505.2 | |||||||||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | |||||||||||||||||
balance-sheet.row.capital-lease-obligations | 9.46 | 3 | 1 | 1.9 | |||||||||||||||||
balance-sheet.row.total-liab | 2480.18 | 660.8 | 571.7 | 578.5 | |||||||||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | |||||||||||||||||
balance-sheet.row.common-stock | 0.42 | 0.1 | 0.1 | 0.1 | |||||||||||||||||
balance-sheet.row.retained-earnings | -5895.67 | -1549.3 | -1340 | -1106.4 | |||||||||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 0 | 0 | 0 | 0 | |||||||||||||||||
balance-sheet.row.other-total-stockholders-equity | 3256.52 | 1094.2 | -0.1 | 0 | |||||||||||||||||
balance-sheet.row.total-stockholders-equity | -2638.73 | -455 | -1340 | -1106.4 | |||||||||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | -158.55 | 205.8 | -768.3 | -527.8 | |||||||||||||||||
balance-sheet.row.minority-interest | 0 | 0 | 0 | 0 | |||||||||||||||||
balance-sheet.row.total-equity | -2638.73 | -455 | -1340 | -1106.4 | |||||||||||||||||
balance-sheet.row.total-liabilities-and-total-equity | -158.55 | - | - | - | |||||||||||||||||
Total Investments | 17.43 | 0 | 84.2 | 100.9 | |||||||||||||||||
balance-sheet.row.total-debt | 1329.61 | 540.9 | 260.9 | 260.2 | |||||||||||||||||
balance-sheet.row.net-debt | 849.15 | 458.7 | 136.2 | 51.3 |
Отчет за паричните потоци
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2002 | 2001 | 2000 | 1999 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | -209.25 | -209.2 | -233.7 | -269.1 | |||||||||||||||||
cash-flows.row.depreciation-and-amortization | 0.16 | 0.2 | 0.5 | 0.6 | |||||||||||||||||
cash-flows.row.deferred-income-tax | -17.56 | 36.5 | 0 | -2.6 | |||||||||||||||||
cash-flows.row.stock-based-compensation | 11.96 | 12 | 15.2 | 24.3 | |||||||||||||||||
cash-flows.row.change-in-working-capital | 13.68 | 13.7 | -3.4 | -52.5 | |||||||||||||||||
cash-flows.row.account-receivables | -14.77 | -14.8 | -10.8 | -10.5 | |||||||||||||||||
cash-flows.row.inventory | -30.42 | -30.4 | -0.8 | -18.3 | |||||||||||||||||
cash-flows.row.account-payables | 8.68 | 8.7 | 5.6 | -34.1 | |||||||||||||||||
cash-flows.row.other-working-capital | 50.18 | 50.2 | 2.6 | 10.4 | |||||||||||||||||
cash-flows.row.other-non-cash-items | 65.52 | 11.5 | 46.5 | 35.5 | |||||||||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | -135.49 | 0 | 0 | 0 | |||||||||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | 0 | 0 | 0 | 0 | |||||||||||||||||
cash-flows.row.acquisitions-net | 0 | 0 | 0 | 0 | |||||||||||||||||
cash-flows.row.purchases-of-investments | 0 | 0 | -59.9 | -50.5 | |||||||||||||||||
cash-flows.row.sales-maturities-of-investments | 42.5 | 42.5 | 68 | 0 | |||||||||||||||||
cash-flows.row.other-investing-activites | 42.5 | 0 | 0 | 0 | |||||||||||||||||
cash-flows.row.net-cash-used-for-investing-activites | 42.5 | 42.5 | 8.1 | -50.5 | |||||||||||||||||
cash-flows.row.debt-repayment | -15.51 | -15.5 | -58.2 | -0.8 | |||||||||||||||||
cash-flows.row.common-stock-issued | 13.52 | 66 | 90.8 | 218.7 | |||||||||||||||||
cash-flows.row.common-stock-repurchased | -0.02 | 0 | 0 | 0 | |||||||||||||||||
cash-flows.row.dividends-paid | 0 | 0 | 0 | 0 | |||||||||||||||||
cash-flows.row.other-financing-activites | 53.81 | 0 | -50.2 | 50.3 | |||||||||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 50.46 | 50.5 | 32.6 | 268.2 | |||||||||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0 | 0 | 0 | 0 | |||||||||||||||||
cash-flows.row.net-change-in-cash | -42.53 | -42.5 | -134.1 | -46.1 | |||||||||||||||||
cash-flows.row.cash-at-end-of-period | 480.46 | 82.2 | 124.8 | 258.9 | |||||||||||||||||
cash-flows.row.cash-at-beginning-of-period | 522.99 | 124.8 | 258.9 | 305 | |||||||||||||||||
cash-flows.row.operating-cash-flow | -135.49 | -135.5 | -174.8 | -263.8 | |||||||||||||||||
cash-flows.row.capital-expenditure | 0 | 0 | 0 | 0 | |||||||||||||||||
cash-flows.row.free-cash-flow | -135.49 | -135.5 | -174.8 | -263.8 |
Ред за отчет за приходите
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2002 | 2001 | 2000 | 1999 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 116.33 | 116.3 | 75.5 | 78.4 | |||||||||||||||||
income-statement-row.row.cost-of-revenue | 43.27 | 43.4 | 27 | 14.2 | |||||||||||||||||
income-statement-row.row.gross-profit | 73.06 | 72.9 | 48.5 | 64.2 | |||||||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | |||||||||||||||||
income-statement-row.row.research-development | 86.11 | - | - | - | |||||||||||||||||
income-statement-row.row.selling-general-administrative | 29.82 | - | - | - | |||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 15.6 | - | - | - | |||||||||||||||||
income-statement-row.row.other-expenses | 22.52 | 5.3 | 2.7 | 4 | |||||||||||||||||
income-statement-row.row.operating-expenses | 248.79 | 228.5 | 228 | 291 | |||||||||||||||||
income-statement-row.row.cost-and-expenses | 271.9 | 271.9 | 255 | 305.2 | |||||||||||||||||
income-statement-row.row.interest-income | 5.11 | 4.8 | 2.6 | 0.1 | |||||||||||||||||
income-statement-row.row.interest-expense | -0.09 | 59 | 56.8 | 46.4 | |||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 15.6 | - | - | - | |||||||||||||||||
income-statement-row.row.total-other-income-expensenet | -53.69 | -53.7 | -54.2 | -42.4 | |||||||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | |||||||||||||||||
income-statement-row.row.other-operating-expenses | 22.52 | 5.3 | 2.7 | 4 | |||||||||||||||||
income-statement-row.row.total-operating-expenses | -53.69 | -53.7 | -54.2 | -42.4 | |||||||||||||||||
income-statement-row.row.interest-expense | -0.09 | 59 | 56.8 | 46.4 | |||||||||||||||||
income-statement-row.row.depreciation-and-amortization | 1.36 | 0.2 | 2.7 | 4 | |||||||||||||||||
income-statement-row.row.ebitda-caps | -154.28 | - | - | - | |||||||||||||||||
income-statement-row.row.operating-income | -155.56 | -155.6 | -179.5 | -226.7 | |||||||||||||||||
income-statement-row.row.income-before-tax | -209.25 | -209.2 | -233.7 | -269.1 | |||||||||||||||||
income-statement-row.row.income-tax-expense | 27.42 | 0 | 54.2 | 49.7 | |||||||||||||||||
income-statement-row.row.net-income | -236.75 | -209.2 | -287.8 | -318.8 |
Често задавани въпроси
Какво е Esperion Therapeutics, Inc. (ESPR) общи активи?
Esperion Therapeutics, Inc. (ESPR) общите активи са 205796000.000.
Какъв е годишният приход на предприятието?
Годишните приходи са 66219000.000.
Какъв е маржът на печалбата на предприятието?
Маржът на печалбата на фирмата е -1.205.
Какъв е свободният паричен поток на компанията?
Свободният паричен поток е -1.205.
Какъв е маржът на нетната печалба на предприятието?
Маржът на нетната печалба е -2.035.
Какъв е общият приход на предприятието?
Общият приход е -1.337.
Каква е Esperion Therapeutics, Inc. (ESPR) нетна печалба (нетен доход)?
Нетната печалба (нетният доход) е -209248000.000.
Какъв е общият дълг на фирмата?
Общият дълг е 540947000.000.
Какъв е броят на оперативните разходи?
Оперативните разходи са 228466000.000.
Какъв е броят на паричните средства на фирмата?
Паричните средства на предприятието са 82248000.000.